|  |
| --- |
| Billing, Reimbursement, and Access for Remdesivir |
| **Outpatient remdesivir administration** * The Centers for Medicare and Medicaid Services (CMS) approved Healthcare Common Procedure Coding System (HCPCS) Code **J0248**
	+ 1mg billing increment, available for all payers, services on or after 12/23/2021
* American Medical Association (AMA) Current Procedural Terminology (CPT) codes

|  |  |
| --- | --- |
| * 96365

IV infusion, for therapy, prophylaxis or diagnosis up to 1 hour | * 96367

IV infusion, for therapy, prophylaxis, or diagnosis, additional sequential infusion of a new drug/substance, up to 1 hour |
| * 96366

IV infusion, for therapy, prophylaxis, or diagnosis, each additional hour | * 96369

IV infusion, for therapy, prophylaxis, or diagnosis; concurrent infusion  |

**Inpatient remdesivir administration** * Medical centers/facilities should contact their respective [Medicare Administrative Contractor (MAC)](https://www.cms.gov/MAC-info) for specific billing instructions
* CMS payment enhancement available under New COVID-19 Treatments Add-on Payment (NCTAP) program for remdesivir (and other COVID-19 therapies)
	+ NCTAP helps to mitigate financial disincentives for medical centers/hospitals to provide new COVID-19 therapeutics
	+ Effective from 11/2/2020 until 9/30/2023 of the COVID-19 public health emergency
	+ NCTAP claims eligibility for 20% add-on payment under section 3710 of the Coronavirus Aid, Relief, and Economic Securities (CARES) Act has EXPIRED 5/11/2023.
	+ NCTAP is equal to the lesser of 65% of operating outlier threshold for the claim OR 65% of the amount by which the costs exceed the standard diagnosis-related group (DRG) payment
	+ More information about NCTAP [here](https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap)
* Medicare DRG enhancement
	+ Section 3710 of the CARES Act allowed for an increase in the weighting factor for a DRG by 20% for an individual diagnosed with COVID-19 and discharged during the public health emergency time period, this however EXPIRED 5/11/2023.
	+ A positive COVID-19 test is required for claims to be eligible

Additional information regarding Coding and Reimbursement for remdesivir is available [here](https://www.vekluryhcp.com/downloads/Coding_and_Reimbursement_information.pdf) Assistance for access to remdesivir is available through the [Gilead Advancing Access](https://www.vekluryhcp.com/access/) program* Offers assistance with co-pay information, coding/reimbursement, verification
* Contact: 1-800-226-2056 (option 4); M-F 0900-2000 EST
 |